See S4
Email me when S 3102 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track S 3102. By continuing you agree to the Terms and Privacy Policy.
Legislative status
- Introduced
- In Committee
- Reported by Committee
- Floor Vote Scheduled
- Passed One Chamber
- Passed Both Chambers
- Sent to Executive
- Signed into Law
Summary
The bill adds new sections to several insurance statutes requiring group health plans, Medicaid managed‑care plans, accident‑and‑sickness policies, hospital service contracts and health‑maintenance contracts to pay for biomarker tests when they are backed by FDA approval, clinical guidelines or other recognized evidence. It also sets rules for prior‑authorization, appeals and rapid response times to prevent care delays. The aim is to ensure patients can obtain needed genetic and molecular tests without extra biopsies or administrative hurdles.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about S 3102
3 free questions a day, no accountSponsors
- Jacob R. Oliveira (D) · sponsor
- Patrick M. O'Connor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when S 3102 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track S 3102 freeOr ask your AI assistant about S 3102 directly:
Add to Claude, ChatGPT or Cursor